Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Vienna, Austria – 21 June 2017: Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with symptoms, according to results from the GLORIA-AF Registry presented today at EHRA EUROPACE - CARDIOSTIM 2017.1 The findings highlight the need for screening to identify atrial fibrillation patients with no symptoms so that stroke prevention treatment can be given.
“Patients with non-valvular atrial fibrillation have a five-fold increased risk of stroke compared to those without atrial fibrillation,” said lead author Dr Steffen Christow, a cardiologist at Hospital Ingolstadt GmbH, Ingolstadt, Germany. “Strokes in patients with non-valvular atrial fibrillation tend to be particularly severe and disabling, with about half of patients dying within one year.”
“Appropriate anticoagulant therapy substantially reduces the risk of stroke, but in many cases non-valvular atrial fibrillation is only diagnosed after a patient has had a stroke,” he continued. “When patients are unaware of their atrial fibrillation they remain untreated and unprotected from stroke.”
GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a large, multinational, prospective registry programme involving patients with newly diagnosed non-valvular atrial fibrillation. This sub-analysis compared characteristics between symptomatic and asymptomatic patients in Western Europe.
The study included 6 011 consecutively enrolled patients with non-valvular atrial fibrillation in Western Europe.2 Symptom status was defined by the European Heart Rhythm Association (EHRA) score: I-II asymptomatic/minimally symptomatic; III-IV symptomatic.
A total of 4 119 patients (two-thirds) were asymptomatic/minimally symptomatic (hereafter referred to as ’asymptomatic‘) and one-third (1 892) were symptomatic at the time of diagnosis. A number of differences were observed between the two groups.
In terms of medical history, asymptomatic patients were twice as likely to have permanent atrial fibrillation (15.8% versus 8.3%) and more than twice as likely to have had a previous stroke (14.7% versus 6.0%) than patients in the symptomatic group. Asymptomatic and symptomatic patients had a similar number of stroke risk factors, as indicated by a CHA2DS2-VASc score of 3.3 in each group.
Dr Christow said: “The finding of a higher rate of previous stroke in the asymptomatic patients despite no differences in the number of stroke risk factors may be explained by a longer but undiagnosed history of atrial fibrillation.”
“Our study found that in Western Europe, two-thirds of patients newly diagnosed with atrial fibrillation were asymptomatic,” he continued. “Without detection, patients may not receive appropriate preventive therapy and remain at increased risk of stroke.”
Dr Christow concluded: “These results underline the urgent need for public programmes to detect atrial fibrillation in the general population.”
ESC Press OfficeTel: +33 (0) 4 89 87 34 83Email: firstname.lastname@example.org
SOURCES OF FUNDING: The study was sponsored by Boehringer Ingelheim. DISCLOSURES: None.References and notes1The abstract ‘Increased rate of previous stroke in asymptomatic/minimally symptomatic versus symptomatic patients with newly detected atrial fibrillation in western Europe - results from the GLORIA-AF registry’ will be presented during Rapid Fire session 8 –Atrial fibrillation and stroke prevention which takes place on 21 June from 08:30 to 10:00 in the Agora.2The Western European region included in the present sub-analysis consists of Austria, Denmark, France, Germany, Greece, Ireland (Republic), Italy, The Netherlands, Norway, Portugal, Spain, Switzerland, United Kingdom and Belgium.About EHRA EUROPACE - CARDIOSTIM EHRA EUROPACE - CARDIOSTIM is an established, international conference attracting key opinion leaders, well-recognised scientists, physicians, allied professionals and industry.About the European Heart Rhythm AssociationThe European Heart Rhythm Association (EHRA) is a registered branch of the European Society of Cardiology (ESC). Its aim is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death. EHRA ensures the dissemination of knowledge and standard setting; provides continuous education, training and certification to physicians and allied professionals involved in the field of cardiac arrhythmias with a special focus on Atrial Fibrillation (AF) and Electrophysiology (EP). EHRA releases international consensus documents and position papers, it is a source of high quality, unbiased, evidence based, scientific information that promotes the quality of care for patients with AF, and for, has also dedicated a website for patients “afibmatters.org”. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.Information for journalists attending EHRA EUROPACE - CARDIOSTIM 2017EHRA EUROPACE - CARDIOSTIM 2017 takes place 18 to 21 June in Vienna, Austria, at the Reed Messe Wien GmbH. The full scientific programme is available here
Our mission: To reduce the burden of cardiovascular disease.
© 2019 European Society of Cardiology. All rights reserved.